Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

Serotonin reuptake inhibitors for depression in PD

Nature Reviews Neurology volume 8, pages 365–366 (2012)Cite this article

Subjects

A recent study to investigate the safety and efficacy of serotonin reuptake inhibitors suggests that these drugs are beneficial for the treatment of depressive disorders in Parkinson disease. Whether these treatments will offer such benefits in the long term compared with other pharmacological and nonpharmacological approaches remains to be determined.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U. & Svenningsson, P. Depression in Parkinson disease—epidemiology, mechanisms and management. Nat. Rev. Neurol. 8, 35–47 (2012).

    Article  CAS  Google Scholar 

  2. Schrag, A. et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov. Disord. 22, 1077–1092 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S42–S80 (2011).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Skapinakis, P. et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 10, 49 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bondon-Guitton, E. et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov. Disord.. 26, 2226–2231 (2011).

    Article  PubMed  Google Scholar 

  6. Richard, I. H. et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 78, 1229–1236 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Menza, M. et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 72, 886–892 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Schulz, K. F. & Grimes, D. A. Blinding in randomised trials: hiding who got what. Lancet 359, 696–700 (2002).

    Article  PubMed  Google Scholar 

  9. Barone, P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573–580 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Nandagopal, J. J. & DelBello, M. P. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin. Pharmacother. 10, 1665–1673 (2009).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Neuroscience, University Hospital, University of Toulouse III, Toulouse, France

    Santiago Perez-Lloret & Olivier Rascol

Authors
  1. Santiago Perez-Lloret
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Rascol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Rascol.

Ethics declarations

Competing interests

O. Rascol has acted as a scientific advisor for Boehringer-Ingelheim in the development of antiparkinsonian medications. He has received unrestricted scientific grants from Novartis, Boehringer-Ingelheim, Eisai, Euthérapie, Faust Pharmaceuticlas, GlaxoSmithKline, Lundbeck, Solvay, and TEVA. S. Perez-Lloret declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez-Lloret, S., Rascol, O. Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 8, 365–366 (2012). https://doi.org/10.1038/nrneurol.2012.111

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.111

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing